• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Sirtris Pharmaceuticals

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact
sirtris

Sirtris Pharmaceuticals

Exit: 2008
Visit Website
  • USA
  • Bradikinin B2 receptor based drugs for angioedema and severe burn, drugs for ophthalmic disease indications
  • Investment Period: 3 years
  • 2007 IPO on NASDAQ,
  • 2008 acquisition by GlaxoSmithKline (GSK) for approximately $720 million (€467 M) through a cash tender offer of $22.50 (€14.59) per share

TVM Capital Life Science provided significant support and guidance to the company from its inception. Specifically, the US-based Partner provided instrumental operations assistance in the structuring and management of company labs, the development of assays, and the development of a strategy to use a contract research organization for medicinal chemistry activities.

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact